Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 13Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Follicular 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Multiple Myeloma 11Leukemia, Myeloid, Chronic-Phase 11Leukemia, Myeloid, Acute 11Sezary Syndrome 10Mycosis Fungoides 10Lymphoma 10Leukemia, Myeloid, Accelerated Phase 10Hodgkin Disease 10Blast Crisis 10Neoplasms, Plasma Cell 9Myeloproliferative Disorders 9Myelodysplastic Syndromes 9Leukemia 9Congenital Abnormalities 9Dendritic Cell Sarcoma, Interdigitating 8Primary Myelofibrosis 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Graft vs Host Disease 7Recurrence 6Leukemia, Myelomonocytic, Chronic 6

Interventions

denileukin diftitox 2Nivolumab 2sargramostim 1peginterferon alfa-2b 1Prednisone 1Phenobarbital 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Irinotecan 1Introns 1Infliximab 1Etoposide 1Dexamethasone 1Cyclosporine 1Cyclophosphamide 1Cisplatin 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Methylprednisolone × Dermatologic × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡